Talquetamab (Anti-CD3 & GPRC5D)

製品コード：A4026        

印刷

Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. MW: 144.6 KD.